Advanced Ovarian Cancer: 20% Disease-Free Survival at 10 Years Advanced Ovarian Cancer: 20% Disease-Free Survival at 10 Years
Maurie Markman, MD, discusses a recent paper on the 10-year survival rate of patients with stage III ovarian cancer.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 7, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

No Survival Benefit for Upfront VEGF Inhibitors in Metastatic CRC No Survival Benefit for Upfront VEGF Inhibitors in Metastatic CRC
In fact, the worst survival outcomes were seen with the most commonly used first-line regimen, FOLFOX chemotherapy plus the VEGF inhibitor bevacizumab.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 6, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

New Trials in Urologic Cancers: Could Your Patient Benefit? New Trials in Urologic Cancers: Could Your Patient Benefit?
Perhaps one of your patients could benefit from clinical trials that are currently recruiting patients with urologic cancers, including prostate cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 6, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Race and Geography Tied to Breast Cancer Care Delays Race and Geography Tied to Breast Cancer Care Delays
A recent study suggests the need to target high-risk geographic regions and patient groups to ensure timely breast cancer care.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 6, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Cath Ablation for AF No Less Safe, Effective in Cancer Patients Cath Ablation for AF No Less Safe, Effective in Cancer Patients
Freedom from recurrence or reablation and safety outcome were similar at 12 months regardless of whether patients had a recent cancer diagnosis or were on anthracyclines.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 3, 2023 Category: Cancer & Oncology Tags: Cardiology News Source Type: news

FDA OKs Sacituzumab Govitecan for HR+ Metastatic Breast Cancer FDA OKs Sacituzumab Govitecan for HR+ Metastatic Breast Cancer
Investigators reported an overall survival benefit of 3.2 months versus single agent chemotherapy in previously treated patients.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 3, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Move Towards Making Extravasations a Reportable Event? Move Towards Making Extravasations a Reportable Event?
Although there has been a move towards making extravasations a reportable medical event, a patient advocacy group says the proposed change places the burden on patients rather than healthcare professionals.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 2, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Does Immunotherapy Offer Survival Gain in Older NSCLC Patients? Does Immunotherapy Offer Survival Gain in Older NSCLC Patients?
Contrary to clinical trial results, the survival benefit of checkpoint inhibitors in the real-world setting is lower among older people with NSCLC, who make up a large proportion of patients.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 1, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Black Patients Less Likely to Receive Opioids for Advanced Cancer Black Patients Less Likely to Receive Opioids for Advanced Cancer
Older Black patients with advanced cancer are less likely than White patients to receive opioids for pain relief yet are more likely to receive drug screenings in the last weeks of life.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 1, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Blacks Less Likely to Receive Opioids for Advanced Cancer Blacks Less Likely to Receive Opioids for Advanced Cancer
Older Black patients with advanced cancer are less likely than White patients to receive opioids for pain relief yet are more likely to receive drug screenings in the last weeks of life.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 1, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Can AI Conquer the Late-Shift Dip in Colonoscopy Quality? Can AI Conquer the Late-Shift Dip in Colonoscopy Quality?
Artificial intelligence may be an effective tool to minimize the well-known, time-related degradation in colonoscopy quality.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 1, 2023 Category: Cancer & Oncology Tags: Gastroenterology News Source Type: news

New Treatment Recommendations for Early-Onset CRC New Treatment Recommendations for Early-Onset CRC
An international group of physicians has issued a list of 31 treatment recommendations for patients diagnosed with early-onset colorectal cancer (before 50 years of age).MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 31, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Chemo in Afternoon Works Better Than in Morning, but Only in Women Chemo in Afternoon Works Better Than in Morning, but Only in Women
For women with diffuse large B-cell lymphoma undergoing chemotherapy, survival was better with less toxicity when the drugs were administered in the afternoon than in the morning.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 31, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Many Patients Don't Receive Indicated Targeted NSCLC Therapy Many Patients Don't Receive Indicated Targeted NSCLC Therapy
The rates of use of targeted therapy among patients with EGFR- and ALK-mutations also varied across the US, dropping below 20% in some states.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 31, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Many People Don't Get Colonoscopy Even After Positive Stool Test Many People Don't Get Colonoscopy Even After Positive Stool Test
A new study shows that almost half of people with a positive stool test don ' t follow-up with a colonoscopy.WebMD Health News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 30, 2023 Category: Cancer & Oncology Tags: Gastroenterology News Source Type: news